成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

化合物 AT7519,AT7519
  • 化合物 AT7519,AT7519

化合物 AT7519|T6205|TargetMol

價(jià)格 285 662 1120
包裝 1mg 5mg 10mg
最小起訂量 1mg
發(fā)貨地 上海
更新日期 2024-09-29
QQ交談 微信洽談

產(chǎn)品詳情

中文名稱:化合物 AT7519英文名稱:AT7519
CAS:844442-38-2品牌: TargetMol
產(chǎn)地: 美國(guó)保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
純度規(guī)格: 99.65%產(chǎn)品類別: 抑制劑
貨號(hào): T6205
2024-09-29 化合物 AT7519 AT7519 1mg/285RMB;5mg/662RMB;10mg/1120RMB 285 TargetMol 美國(guó) Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. 99.65% 抑制劑

Product Introduction

Bioactivity

名稱AT7519
描述AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.
細(xì)胞實(shí)驗(yàn)Cells are incubated with different concentrations of AT7519 for 24 or 48 hours at 37 °C. Cell viability is assessed by measuring 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyl tetrasodium bromide (MTT) dye absorbance. DNA synthesis is measured by tritiated thymidine uptake (3H-TdR). Apoptosis is assessed by using Annexin V/PI staining. The percentage of cells undergoing apoptosis is defined as the sum of early apoptosis (Annexin V-positive cells) and late apoptosis (Annexin V-positive and PI-positive cells(Only for Reference)
激酶實(shí)驗(yàn)In vitro Kinase Assays: Kinase assays for CDK1, CDK2 and GSK3-β are all carried out in a radiometric filter binding format. Assays for CDK5 are in DELFIA format and for CDKs 4 and 6 in ELISA format. For CDKs 1 and 2, the relevant CDK and 0.12 μg/mL Histone H1 are incubated in 20 mM MOPS, pH 7.2, 25 mM β-glycerophosphate, 5 mM EDTA, 15 mM MgCl2, 1 mM sodium orthovanadate, 1 mM DTT, 0.1 mg/mL BSA, 45 μM ATP (0.78 Ci/mmol) and different concentrations of AT7519 for 2 or 4 hours respectively. For GSK3-β, the relevant enzyme and 5 μM glycogen synthase peptide 2 along with 10 mM MOPS pH 7.0, 0.1 mg/mL BSA, 0.001% Brij-35, 0.5% glycerol, 0.2 mM EDTA, 10 mM MgCl2, 0.01% β-mercaptoethanol, 15 μM ATP (2.31 Ci/mmol) and different concentrations of AT7519 are incubated for 3 hours. Assay reactions are stopped by adding an excess of orthophosphoric acid and filtered using Millipore MAPH filter plates. The plates are then washed, scintillant added and radioactivity measured by scintillation counting on a Packard TopCount. For CDK5, CDK5/p35 and 1 μM of a biotinylated Histone H1 peptide (Biotin-PKTPKKAKKL) are incubated in 25 mM Tris-HCl, pH 7.5, 2.5 mM MgCl2, 0.025% Brij-35, 0.1 mg/mL BSA, 1 mM DTT, 15 μM ATP and different concentrations of AT7519 for 30 minutes. Assay reactions are stopped using EDTA, transferred to Neutravidin-coated plates and phosphorylated peptide quantified by means of a rabbit phospho-cdk1 substrate polyclonal antibody and DELFIA europium-labelled anti-rabbit IgG secondary antibody using time-resolved fluorescence at λex=335 nM, λem=620 nM. For CDK 4 and 6 assays, plates are coated with GST- pRb769-921 and blocked with Superblock. CDK4 or 6 is incubated with 15 mM MgCl2, 50 mM HEPES, pH 7.4, 1 mM DTT, 1 mM EGTA, pH 8.0, 0.02% Triton X-100, 2.5% DMSO and different concentrations of AT7519; the reaction is initiated by addition of ATP. After 30 minutes, reactions are stopped by the addition of 0.5 M EDTA pH 8.0.Plates are then washed and incubated for one hour with the primary antibody (anti- p-Rb Serine 780) diluted in Superblock followed by secondary antibody (alkaline phosphatase linked anti-rabbit) for a further hour. Plates are developed using the Attophos system and fluorescence read on a Spectramax Gemini plate reader at excitation 450 nm and emission 580 nm. In all cases, IC50 values are calculated from replicate curves, using GraphPad Prism software.
體外活性AT7519是一種與ATP競(jìng)爭(zhēng)的CDK抑制劑,對(duì)CDK1的Ki值為38 nM,除了對(duì)GSK3β(IC50 = 89 nM)有活性外,對(duì)所有非CDK激酶均無(wú)活性。AT7519在多種人類腫瘤細(xì)胞系中顯示出強(qiáng)大的抗增殖活性,IC50值從MCF-7的40 nM到SW620的940 nM不等,這與CDK1和CDK2的抑制作用一致。[1] AT7519在48小時(shí)內(nèi)對(duì)多發(fā)性骨髓瘤(MM)細(xì)胞系產(chǎn)生劑量依賴性的細(xì)胞毒性,IC50值從0.5到2 μM不等,對(duì)MM.1S(0.5 μM)和U266(0.5 μM)細(xì)胞系最為敏感,而對(duì)MM.1R(>2 μM)最為耐藥。它不對(duì)外周血單核細(xì)胞(PBMNC)產(chǎn)生細(xì)胞毒性。AT7519部分克服了IL6和IGF-1提供的增殖優(yōu)勢(shì)以及骨髓基質(zhì)細(xì)胞(BMSCs)的保護(hù)效果。AT7519快速促進(jìn)RNA pol II CTD在絲氨酸2和絲氨酸5位點(diǎn)的去磷酸化,并導(dǎo)致轉(zhuǎn)錄抑制,這部分地促成了AT7519對(duì)MM細(xì)胞誘導(dǎo)的細(xì)胞毒性。通過(guò)下調(diào)GSK-3β的磷酸化,AT7519激活GSK-3β,這也促成了AT7519誘導(dǎo)的凋亡,這一過(guò)程與轉(zhuǎn)錄抑制無(wú)關(guān)。[2]
體內(nèi)活性每日兩次給藥AT7519(9.1 mg/kg)能夠促使HCT116與HT29結(jié)腸癌異種移植模型中的早期和晚期s.c.腫瘤退化。[1] AT7519治療(15 mg/kg)抑制了人類MM異種移植小鼠模型中的腫瘤生長(zhǎng),并與caspase 3活化增加相關(guān),延長(zhǎng)了小鼠的中位總生存時(shí)間。[2]
存儲(chǔ)條件Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
溶解度H2O : < 1 mg/mL (insoluble or slightly soluble)
Ethanol : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 16.67 mg/mL (43.6 mM)
關(guān)鍵字AT 7519 | inhibit | Apoptosis | CDK | AT-7519 | Inhibitor | AT7519M | AT7519 | Cyclin dependent kinase
相關(guān)產(chǎn)品Lidocaine hydrochloride | Metronidazole | 5-Fluorouracil | Stavudine | Tributyrin | Dextran sulfate sodium salt (MW 4500-5500) | Myricetin | Sorafenib | L-Ascorbic acid | Acetylcysteine | Sodium 4-phenylbutyrate | Kaempferol
相關(guān)庫(kù)神經(jīng)保護(hù)化合物庫(kù) | 抑制劑庫(kù) | 抗癌活性化合物庫(kù) | 經(jīng)典已知活性庫(kù) | 已知活性化合物庫(kù) | 激酶抑制劑庫(kù) | 抗衰老化合物庫(kù) | 藥物功能重定位化合物庫(kù) | 抗癌臨床化合物庫(kù) | 抗癌藥物庫(kù)
關(guān)鍵字: AT7519|TargetMol

公司簡(jiǎn)介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓,致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個(gè)國(guó)家和地區(qū),已發(fā)展成為全球知名的化合物庫(kù)和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫(kù),以及多種類型的生化試劑產(chǎn)品,包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等,此外,我們還建設(shè)有CADD(計(jì)算機(jī)輔助藥物設(shè)計(jì))研究中心、藥理實(shí)驗(yàn)室、藥化合成平臺(tái)三大技術(shù)中心,全方位滿足客戶的定制需求。 憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持,我們將有效幫助您縮短研發(fā)周期,取得更成功的結(jié)果。
成立日期 2013-04-18 (12年) 注冊(cè)資本 566.265100萬(wàn)人民幣
員工人數(shù) 100-500人 年?duì)I業(yè)額 ¥ 1億以上
主營(yíng)行業(yè) 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) 經(jīng)營(yíng)模式 貿(mào)易,工廠,試劑,定制,服務(wù)
  • TargetMol中國(guó)(陶術(shù)生物)
VIP 3年
  • 公司成立:12年
  • 注冊(cè)資本:566.265100萬(wàn)人民幣
  • 企業(yè)類型:有限責(zé)任公司(自然人投資或控股)
  • 主營(yíng)產(chǎn)品:小分子抑制劑、藥物篩選化合物庫(kù)、藥物篩選等
  • 公司地址:靜安區(qū)江場(chǎng)三路238號(hào)8樓
詢盤

化合物 AT7519|T6205|TargetMol相關(guān)廠家報(bào)價(jià)

產(chǎn)品名稱 價(jià)格   公司名稱 報(bào)價(jià)日期
詢價(jià)
VIP2年
上海嘉定區(qū)澄瀏公路52號(hào)
2024-11-06
¥1279.90
VIP13年
上海阿拉丁生化科技股份有限公司
2024-10-31
詢價(jià)
南京百鑫德諾生物科技有限公司
2024-09-26
¥720.90
VIP1年
上海阿拉丁生化科技股份有限公司
2024-08-16
詢價(jià)
VIP5年
廣州優(yōu)南科技有限公司
2024-07-04
內(nèi)容聲明:
以上所展示的信息由商家自行提供,內(nèi)容的真實(shí)性、準(zhǔn)確性和合法性由發(fā)布商家負(fù)責(zé)。 商家發(fā)布價(jià)格指該商品的參考價(jià)格,并非原價(jià),該價(jià)格可能隨著市場(chǎng)變化,或是由于您購(gòu)買數(shù)量不同或所選規(guī)格不同而發(fā)生變化。最終成交價(jià)格,請(qǐng)咨詢商家,以實(shí)際成交價(jià)格為準(zhǔn)。請(qǐng)意識(shí)到互聯(lián)網(wǎng)交易中的風(fēng)險(xiǎn)是客觀存在的